Futura's ED treatment gel receives approval in Saudi Arabia

Published: 14-Aug-2023
Distribution Manufacturing Regulatory

Futura Medical's distribution partner Labatec Pharma has received received regulatory approval for MED3000, the gel-based ED treatment, in Saudi Arabia

Pharmaceutical company Futura Medical has announced that its distribution partner Labatec Pharma has received regulatory approval for MED3000, Futura's innovative topical, gel-based Erectile Dysfunction (ED) treatment, in the Kingdom of Saudi Arabia.

Labatec will exclusively launch and commercialise MED3000 under the brand name Eroxon, with initial launch planned in Q4 2023. The manufacturing of Eroxon for the launch has been completed and it will be supported by a full marketing campaign. Saudi Arabia is one of the top ten ED markets in the world by value, with a reported 10.45% of married males experiencing ED.

Labatec will hold a launch symposium showcasing Eroxon at the 20th Urological Association of Asia Congress 2023, which is being held from 28 September to 1 October in conjunction with the 12th Emirates International Urological conference in Dubai, United Arab Emirates.

Regulatory approval in the Kingdom of Saudi Arabia paves the way for Eroxon to improve the lives of ED patients in this key market

- James Barder, CEO of Futura

Futura is establishing a growing network of licencing and distribution partners and continues to strengthen its position, with regulatory approval having now been granted in six Middle Eastern countries, including the Kingdom of Saudi Arabia and the United Arab Emirates. Regulatory approval in the Kingdom of Saudi Arabia closely follows Futura's recent European and UK launch of Eroxon and the FDA's approval of MED3000 in the USA as the first clinically proven gel for the treatment of ED available without a doctor's prescription.

James Barder, CEO of Futura said: "Regulatory approval in the Kingdom of Saudi Arabia paves the way for Eroxon to improve the lives of ED patients in this key market. Eroxon is a game changer in the ED space with its rapid speed of onset helping men get an erection within 10 minutes. This approval comes at a pivotal time for the company, as we continue to grow and expand the availability of MED3000 globally by building out our licensing and distribution network."

  • Companies:
  • Futura Medical
See more

You may also like

Distribution

Futura expands partnership with M8 Pharmaceuticals for remainder of Central and South American region

Read more
Futura Medical is pleased to announce that M8 Pharmaceuticals has taken up its rights to extend its licensing agreement from Brazil and Mexico to market MED3000 in a further 14 countries throughout the Central and South American region

Trending Articles

  1. TekniPlex Healthcare to showcase expanded capacity and sustainability solutions at Pharmapack Company highlights EU-based advancements in injection blow molding, multilayer blown films, and sustainable blister packaging
  2. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles
  5. The Guardtech Group Industry-leading providers of bespoke laboratory design & build solutions, as well as a wide array of high-quality cleanroom-related products and services – including comprehensive decontamination and maintenance programmes

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Distribution

Futura expands partnership with M8 Pharmaceuticals for remainder of Central and South American region

Futura Medical is pleased to announce that M8 Pharmaceuticals has taken up its rights to extend its licensing agreement from Brazil and Mexico to market MED3000 in a further 14 countries throughout the Central and South American region
Manufacturing

ACG expands global footprint with new capsule manufacturing facility in Thailand

New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
Regulatory

Accelerating and enhancing toxicology assessments

Infographic guides users through ToxHQ’s speedy assessment features
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Manufacturing

Scinai Immunotherapeutics establishes Delaware-based US CDMO subsidiary

The biopharmaceutical company now operates contract development and manufacturing services in both Jerusalem and Delaware
Distribution

Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01

The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
Manufacturing

£20m Scottish oligonucleotide manufacturing innovation centre now under construction

The centre will act as an innovation centre, assisting in the development and optimisation of oligonucleotide manufacturing processes, while also bolstering the UK's biopharmaceutical presence
Subscribe now